Delving into the Latest Updates on Pulmovinci with Synapse

Overview

Basic Info

Drug Type

Cell therapy

Synonyms

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

Endocrinology and Metabolic DiseaseRespiratory DiseasesOther Diseases

Active Indication

Idiopathic Pulmonary FibrosisPulmonary Disease, Chronic ObstructiveThyroid Hormone Plasma Membrane Transport Defect

Inactive Indication-

Originator Organization

XLotus Therapeutics Co, Ltd.

Active Organization

Regend Therapeutics Co Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

RegulationOrphan Drug (United States)

Login to view timeline

Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of lung tissues. REGEND001 is a cell therapy product, made from bronchial basal cells with ability to regenerate lung tissue, is promising to IPF treatment. This is a multi-center, randomized, double-blinded, parallel and placebo-controlled phase II clinical study to evaluate the efficacy and safety of REGEND001 in IPF patients.

Start Date30 Jun 2023

Sponsor / Collaborator

Regend Therapeutics Co Ltd.

[+3]

CTR20231266

/ RecruitingPhase 2

一项评价REGEND001 细胞自体回输制剂移植治疗特发性肺纤维化患者有效性、安全性的多中心、随机、双盲、安慰剂平行对照II 期临床研究

[Translation] A multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of autologous retransfusion of REGEND001 cells in the treatment of patients with idiopathic pulmonary fibrosis

评价REGEND001 细胞自体回输制剂移植治疗特发性肺纤维化患者的有效性、安全性。

[Translation]

To evaluate the efficacy and safety of autologous REGEND001 cell transplantation in the treatment of patients with idiopathic pulmonary fibrosis.

Start Date30 Jun 2023

Sponsor / Collaborator

XLotus Therapeutics Co, Ltd.

CTR20220371

/ Active, not recruitingPhase 2

REGEND001细胞自体回输制剂移植治疗肺弥散功能障碍的慢性阻塞性肺疾病（COPD）的探索性临床研究（多中心、随机、单盲、安慰剂平行对照）

[Translation] An exploratory clinical study of autologous retransfusion of REGEND001 cells for the treatment of chronic obstructive pulmonary disease (COPD) with pulmonary diffusion dysfunction (multicenter, randomized, single-blind, placebo-controlled)

评价REGEND001细胞自体回输制剂移植治疗肺弥散功能障碍的慢性阻塞性肺疾病（COPD）的有效性、安全性。

[Translation]

To evaluate the efficacy and safety of autologous REGEND001 cell transplantation in the treatment of chronic obstructive pulmonary disease (COPD) with pulmonary diffusion dysfunction.

Start Date20 Jun 2022

Sponsor / Collaborator

XLotus Therapeutics Co, Ltd.

100 Clinical Results associated with Pulmovinci

Login to view more data

100 Translational Medicine associated with Pulmovinci

Login to view more data

100 Patents (Medical) associated with Pulmovinci

Login to view more data

100 Deals associated with Pulmovinci

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Idiopathic Pulmonary Fibrosis	Phase 2	China	Regend Therapeutics Co Ltd.	30 Jun 2023
Pulmonary Disease, Chronic Obstructive	Phase 2	China	Regend Therapeutics Co Ltd.	20 Jun 2022
Thyroid Hormone Plasma Membrane Transport Defect	Phase 2	China	Regend Therapeutics Co Ltd.	20 Jun 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CTR20210349 (Literature) Manual	Phase 1	Idiopathic Pulmonary Fibrosis	12	REGEND001 0.6x, 1x, 2x and 3.3× 106 cells/kg	(hpnxhbqyjv) = None hblitnhiux (uelphxveda ) View more	Positive	30 Jan 2025